Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

Core Insights - Hikma Pharmaceuticals has launched TYZAVAN, a ready-to-use vancomycin premix with room-temperature stability, aimed at improving the treatment of sepsis and other infections in a timely manner [1][3]. Product Overview - TYZAVAN is a glycopeptide antibacterial indicated for treating septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections in patients aged 1 month and older [2][21]. - The product is the only FDA-approved vancomycin injection that can be stored at room temperature, eliminating the need for compounding and accelerating treatment [3]. Market Need - Sepsis is a critical health issue in the U.S., with a diagnosis occurring every 20 seconds and a related death every two minutes. Rapid antibiotic administration is essential for improving survival rates, which decrease by 15% after 87–113 minutes [4]. Company Commitment - Hikma emphasizes its R&D capabilities in developing innovative healthcare solutions that enhance patient care, particularly in urgent situations. The company aims to streamline the administration of essential medicines [5]. Product Features - TYZAVAN offers several advantages, including: - Ready-to-use formulation that reduces preparation complexity and handling risks [6]. - Available in seven strengths (0.5g–2g) for flexible dosing [7]. - A shelf life of 16 months without refrigeration, compatible with automated dispensing systems [7].